ACC.23/WCC – Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by principal investigator, Dr Roberto Diletti (Thoraxcenter, Erasmus Medical Center, NL) to explore the findings of the BIOVASC Trial (NCT03621501).
The primary objective of the BIOVASC Trial was to investigate whether an immediate complete revascularization is non inferior to a staged complete revascularization strategy.
The trial results presented at ACC.23 showed that in ACS patients with multivessel coronary artery disease, an immediate complete revascularization strategy was non inferior to a staged complete revascularization for the composite primary outcome and was associated with lower rates of myocardial infarction and unplanned ischaemia driven revascularization at one-year follow-up.
For more content from ACC.23/WCC and the Late-breaker Discussion series head to Late-Breaking Science Video Collection.
Recorded on site at ACC 2023, New Orleans.
Editor: Mirjam Boros
Video production: Oliver Miles & Dan Brent